Travere Therapeutics, Inc. (TVTX) · Sep 21, 2026 · Exec change

Travere taps Bradley Campbell as CEO with $20M-plus equity package

CEO succession — Starts December 1, 2026; approximately $20.25M in equity awards

Travere is changing CEOs as FILSPARI scales, offering Bradley Campbell a large equity package that raises execution stakes.

Travere is moving from a FILSPARI-led commercial launch into a broader rare-kidney platform: FILSPARI demand is accelerating across IgAN and FSGS, while pegtibatinase is in Phase 3 for HCU and civorebrutinib expands the pipeline. The filing changes the leadership of that expansion. Bradley Campbell is contracted to become President and Chief Executive Officer on December 1, 2026, with a board seat tied to his employment. 〔0〕 〔1〕 This is a genuine new disclosure, not a routine confirmation; the filing does not provide a reason for the succession or describe outgoing CEO Eric Dube’s future role.

Compensation elementStated terms
Base salary$1.0 million annually (Section 3.1)
Target annual bonus85% of base salary, or $850,000 at target (Section 3.2)
Initial stock optionApproximately $8.25 million (Section 3.3(a))
Initial time-based RSUsApproximately $8.25 million (Section 3.3(a))
Planned 2027 performance RSUsApproximately $3.75 million (Section 3.3(b))
Expense payment$500,000, subject to repayment in some early-departure cases (Section 4.3)

The package is unusually substantial because it is designed to lock in a CEO for a growth-and-execution phase. The agreement provides roughly $20.25 million of stated equity value, mostly vesting over four years, alongside $1.85 million of target annual cash compensation. 〔2〕 〔3〕 〔4〕 The performance award is tied to future corporate, clinical and/or regulatory milestones, which aligns the hire with the company’s next leg of commercial and pipeline delivery rather than just maintaining the existing business.

The business impact is important but not yet measurable. Travere’s recent operating story is strong—second-quarter FILSPARI sales reached $141.1 million, up 96% year over year, with 2,012 new patient start forms—so the leadership change arrives during execution, not a turnaround. The risk is transition: Campbell inherits a company that must convert FSGS launch momentum into durable growth while funding and advancing pegtibatinase and newer pipeline assets. The filing gives no new operating targets, strategic shift, or evidence that performance has deteriorated.

Bottom line: This is a meaningful CEO succession, not a routine executive reshuffle. The large, milestone-linked package signals that Travere is hiring for the next growth phase, but the filing leaves the central question—whether Campbell can sustain current commercial momentum—unanswered.

What to watch next

Bradley Campbell starts as CEO, December 1, 2026

Original filing on SEC EDGAR

More Travere Therapeutics, Inc. news

Travere taps Bradley Campbell as CEO with $20M-plus equity package | TVTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.